Florri Feme Pharmaceuticals Limited – Trademark Portfolio
Entity Type: 03
Florri Feme Pharmaceuticals Limited owns a portfolio of 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as HEMÉ PAD, PHARMA'RUB, and BREAST NURSE. Of these, 3 are registered. The portfolio spans 3 Nice Classification classes, led by Class 10 (Medical Apparatus) and Class 5 (Pharmaceuticals). Headquartered in Leeds.
The Maltings, Primrose Place
Burton Row, Beeston;
Leeds LS11 5NX , GB
Showing of trademarks Trademarks
Trademark Classifications
Florri Feme Pharmaceuticals Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Florri Feme Pharmaceuticals Limited have?
Florri Feme Pharmaceuticals Limited has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 1 cancelled.
What trademark classes does Florri Feme Pharmaceuticals Limited file in?
Florri Feme Pharmaceuticals Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Florri Feme Pharmaceuticals Limited's most well-known trademarks?
Florri Feme Pharmaceuticals Limited's registered trademark portfolio includes well-known marks such as HEMÉ PAD, PHARMA'RUB, and BREAST NURSE. These are among 3 currently registered trademarks in the portfolio.
What is Florri Feme Pharmaceuticals Limited's trademark registration success rate?
Florri Feme Pharmaceuticals Limited has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.